Abstract 386P
Background
Wnt/β-catenin pathway is closely related to the development and progression of laryngeal squamous cell carcinoma (LSCC). Loss or reduction of ubiquitination and degradation of β-catenin in cytoplasm result in its accumulation in the nucleus and over-activation of the Wnt/β-catenin pathway. Folate receptor 1 (FRα) is overexpressed in numerous epithelial malignancies. However, the effect of FRα on Wnt/β-catenin pathway and its role in LSCC remains unclear.
Methods
Real-time RT-PCR, Western blot and immunohistochemistry(IHC) detects the mRNA and protein level of FRα in 30 cases of laryngeal squamous cell carcinoma (LSCC) tissues and adjacent normal tissues; Flag-FRα and Si# FRα plasmids were constructed and transfected to establish high FRα expression and low FRα expression cells; EdU assay, colony formation, scratch assay and transwell assay were performed to detect the of proliferation, colony formation, migration and invasion ability of cells; SiRNA#β-catenin was used to block Wnt/β-catenin signal and detected the ability of proliferation, colony formation, migration and invasion; confocal laser detects the subcellular distribution of β-catenin; SgRNA#EGFR was used to silence EGFR signal ; co-immunoprecipitation detects the ubiquitination level of β-catenin.
Results
Q-RT-PCR, WB and IHC showed that the mRNA and protein level of FRα in laryngeal carcinoma tissues was significantly higher than adjacent tissues, and the difference was statistically significant (P<0.01). Compared with FRα low expression (TU177/Flag and TU212/Si-FRα) cells, the proliferation, colony formation, migration and invasion abilities of FRα high expression (TU177/Flag-FRα and TU212/Si-NC) cells were enhanced; SiRNA#β-catenin inhibited FRα -induced cell proliferation, colony formation and migration. Confocal laser results showed that the nuclear accumulation of β-catenin was increased in FRα high expression cells. SgRNA#EGFR inhibited FRα -induced nuclear translocation of β-catenin. Co-immunoprecipitation results displayed that the ubiquitination of β-catenin was decreased in FRα high expression cells.
Conclusions
FOLR1 stabilized β-catenin promotes laryngeal carcinoma progression through EGFR signa.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H.Tuo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract